ADVM Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced presentations on the company’s gene therapy programs to be presented at the Association for Vision and Ophthalmology (ARVO) 2020 Congress in Baltimore, MD.

Oral Presentation Title: Phase 1 Study of Intravitreal Gene Therapy ADVM-022 for Neovascular AMD (OPTIC Trial) Presentation: #1154Session Title: AMD Clinical Trials (Session #212) in Ballroom 1Date: Monday, May 4, 2020Time: 8:15 – 8:30 a.m. ET

Poster Title: Intravitreal Delivery of AAV2.7m8. Ranibizumab Suppresses Exudative Lesions in the NHP Laser Induced Model of nAMDPoster Board: #4492 – B0125Poster Session: Gene Therapy and Delivery (Session #488)Date: Wednesday, May 6, 2020Time: 3:00 – 4:45 p.m. ET

Poster Title: Mouse Studies Support Intravitreal Gene Therapy for Blue Cone MonochromacyPoster Board: #4499 - B0132Poster Session: Gene Therapy and Delivery (Session #488)Date: Wednesday, May 6, 2020Time: 3:00 – 4:45 p.m. ET

About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.

Investor and Media Inquiries:

Investors:Myesha LacyAdverum Biotechnologies, Inc.mlacy@adverum.com1-650-649-1257

Media:Cherilyn Cecchini, M.D.LifeSci Communicationsccecchini@lifescicomms.com1-646-876-5196